Cytokinetics, Incorporated
CYTK
$77.22
$2.413.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 105.82M | 88.04M | 87.21M | 85.74M | 19.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.82M | 88.04M | 87.21M | 85.74M | 19.22M |
| Cost of Revenue | 411.87M | 414.45M | 403.68M | 389.06M | 356.10M |
| Gross Profit | -306.06M | -326.41M | -316.47M | -303.32M | -336.88M |
| SG&A Expenses | 331.80M | 284.27M | 254.89M | 242.08M | 227.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 746.06M | 700.30M | 660.14M | 632.72M | 584.86M |
| Operating Income | -640.25M | -612.26M | -572.93M | -546.98M | -565.64M |
| Income Before Tax | -829.61M | -784.96M | -751.94M | -606.31M | -615.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -829.61 | -784.96 | -751.94 | -606.31 | -615.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -829.61M | -784.96M | -751.94M | -606.31M | -615.26M |
| EBIT | -640.25M | -612.26M | -572.93M | -546.98M | -565.64M |
| EBITDA | -629.04M | -602.13M | -563.29M | -537.60M | -556.14M |
| EPS Basic | -6.87 | -6.56 | -6.31 | -5.12 | -5.31 |
| Normalized Basic EPS | -3.66 | -3.47 | -3.31 | -3.20 | -3.32 |
| EPS Diluted | -6.87 | -6.56 | -6.31 | -5.12 | -5.31 |
| Normalized Diluted EPS | -3.66 | -3.47 | -3.31 | -3.20 | -3.32 |
| Average Basic Shares Outstanding | 482.82M | 478.04M | 476.01M | 473.71M | 463.50M |
| Average Diluted Shares Outstanding | 482.82M | 478.04M | 476.01M | 473.71M | 463.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |